Endobronchial ultrasound-guided re-biopsy of non-small cell lung cancer with acquired resistance after EGFR tyrosine kinase inhibitor treatment.

Thorac Cancer · 2023 · PMC9891861 · PMID 36525475

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The use of a first‐generation EGFR‐TKI was associated with occurrence of the T790M mutation, and re‐biopsy of the metastatic site showed a trend toward an association with a higher T790M mutation rate.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.